AEON Biopharma

Positives: management pivoted to an analytical‑first biosimilar strategy that, if successful, could be more capital‑efficient than running multiple 351(a) programs; it renegotiated with Daewoong to reduce debt materially; and it continues to use equity/warrant tools to finance critical milestones.

Negatives: heavy reliance on dilutive financings (public offerings, PIPEs, pre‑funded and milestone warrants) and complex derivative/warrant accounting that has driven volatile P&L. This capital stack raises future dilution risk and complicates per‑share economics until the program de‑risks.

The Daewoong license and supply terms are strategically attractive (exclusive therapeutic rights, no milestones/royalties, agreed transfer price), but execution is the primary value driver.